文章核心观点 - 公司Autonomix与RF Innovations签订协议,获得Apex 6射频消融发生器的非独家全球许可,该发生器已获FDA批准用于疼痛管理 [1][2][3][4] - 该交易有助于简化Autonomix的监管策略,并将该技术应用于公司的治疗领域,以推动其管线的价值 [4] - Autonomix正在开发用于治疗胰腺癌相关疼痛的技术,现有方法如使用阿片类药物或酒精注射只能提供有限缓解,且可能导致严重副作用 [6][8] - Autonomix的技术平台包括一种基于导管的微芯片传感阵列,可检测和区分神经信号,敏感度比现有技术高3000倍,有望实现全身任何部位的血管内诊断和治疗 [7][8] 公司概况 - Autonomix是一家专注于开发创新技术以革新涉及神经系统疾病诊断和治疗方式的医疗器械公司 [7] - 公司正在开发用于治疗疼痛的首创技术,初期临床试验集中于胰腺癌 [6][8] - 该技术平台有望应用于心脏病学、高血压和慢性疼痛管理等多个适应症 [8] - 该技术目前仍处于研发阶段,尚未获得美国FDA的上市批准 [8] 交易信息 - Autonomix以25万股普通股的对价获得Apex 6发生器的永久非独家全球免版税许可 [3] - 该交易有助于简化Autonomix的监管策略,因为Apex 6发生器已获FDA批准用于疼痛管理 [4] - 双方将立即开始合作,将RF Innovations的制造合作伙伴纳入Autonomix的供应链 [5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 21 Waterway Avenue, Suite 300 The Woodlands, Texas 77380 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, including Area Code: (713) 588-6150 Securities Registered Pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Nam ...

CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer Exhibit 99.1 Topline data from first five patients in proof-of-concept (P ...